Latest News for: parp

Edit

Whole-genome sequencing may optimize PARP inhibitor use (Cornell University)

Public Technologies 14 Jan 2026
Tumors with this defect are vulnerable to PARP inhibitors, which further disrupt DNA repair, causing cancer cells to accumulate DNA damage and die ... if patients will benefit from PARP inhibitors.
Edit

Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel ...

Norfolk Daily News 20 Dec 2025
FDA approval is based on the positive results of TRITON3, a ...
Edit

Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial

PR Newswire 19 Dec 2025
The approval is supported by the pivotal TRITON3 Phase 3 trial, which demonstrated that Rubraca is the first and only PARP inhibitor to exceed the efficacy of docetaxel in a direct, head-to-head ...
Edit

Medicalgorithmics has signed an agreement with PARP. The company will receive PLN 9.4 million for the development of a project based on VCAST technology (Medicalgorithmics SA)

Public Technologies 18 Dec 2025
Medicalgorithmics, a Warsaw Stock Exchange-listed developer of globally innovative AI solutions for the cardiology industry, has signed an agreement with PARP to support its innovative Kardiobeat.CT project.
  • 1

Article Search

tools
×
×
×
×